Greg Keenan - 28 Feb 2025 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Signature
/s/ Stephen Robertson, Attorney-in-Fact for Greg Keenan, M.D.
Issuer symbol
AUPH
Transactions as of
28 Feb 2025
Net transactions value
-$97,912
Form type
4
Filing time
04 Mar 2025, 20:59:49 UTC
Previous filing
12 Nov 2024
Next filing
07 Mar 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUPH Common Stock Award $0 +62,583 +56% $0.000000 174,028 28 Feb 2025 Direct F1
transaction AUPH Common Stock Sale $97,912 -12,239 -7% $8.00 161,789 03 Mar 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AUPH Employee Stock Option (right to buy) Award $0 +95,570 $0.000000 95,570 28 Feb 2025 Common Stock 95,570 $7.55 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.
F2 Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the January 30, 2024 grant.
F3 The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.